与粉样β的交叉相互作用驱动TDP-43的粉样原性核心区域内的致病性结构转变
Adam J Gatch1,2, Feng Ding1
1Department of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States.
ACS chemical neuroscience
|April 1, 2025
概括
阿尔茨海默病 (AD) 涉及粉样β (Aβ) 和病理. 新的研究表明,Aβ42纤维素可以触发TARDNA结合蛋白43 (TDP-43) 的有害结构变化,促进其在AD中的聚合.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 计算生物学 计算生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种流行的神经退行性疾病,其特点是粉样β (Aβ) 和聚合物.
- 一部分AD患者还显示TAR DNA结合蛋白43 (TDP-43) 聚合物,与认知衰退恶化相关.
- 已知TDP-43与Aβ的相互作用会影响Aβ的毒性和组合,但Aβ对TDP-43结构和聚合的影响尚不清楚.
研究的目的:
- 调查Aβ42与TDP-43.3的氨基基基核区域 (ACR) 之间的直接相互作用.
- 阐明Aβ42如何影响TDP-43的ACR的结构动态和聚合倾向.
主要方法:
- 利用了全原子离散分子动力学模拟.
- 研究了单体Aβ42与TDP-43 ACR的结合.
- 模拟的ACR二分化和ACR与Aβ42纤维细胞种子的相互作用.
主要成果:
- 单体Aβ42通过分子间键强烈与TDP-43 ACR结合.
- Aβ42纤维种子诱导ACR的显著结构变化,包括螺旋区域的展开.
- Aβ42纤维种子催化了ACR单体之间的并行,在注册表中的分子间β片的形成,促进了异常聚合.
结论:
- 特别是纤维状形式的Aβ42可以催化TDP-43 ACR中的病原性结构转化.
- 这种相互作用可能会启动在阿尔茨海默病患者的一个子集中观察到的TDP-43异常聚合.
- 提供了关键的理论见解,了解AD中TDP-43病理的基础分子机制.
更多相关视频
07:14Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
Published on: February 25, 2022
5.9K
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.7K
相关概念视频
03:03Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350